Chai Discovery Announces $70 million Series A To Transform Molecular Design

Chai Discovery 宣布获得 7000 万美元 A 轮融资，推动分子设计变革

• Fundraise follows foundation model breakthrough in fully de novo antibody design with the Chai-2 series of models

• 募款活动遵循基础模型在完全从头抗体设计方面的突破，采用了Chai-2系列模型。

• Menlo Ventures-led round takes total funding to $100M

Menlo Ventures领投的一轮融资使总融资额达到1亿美元。

• Former Pfizer Chief Scientific Officer Mikael Dolsten, M.D., PhD., joins board

• 前辉瑞首席科学官Mikael Dolsten博士加入董事会

SAN FRANCISCO, August 6, 2025-- Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules to accelerate life-changing therapeutics, today announced its $70 million Series A financing round.

旧金山，2025年8月6日——Chai Discovery是一家预测并重新编程生化分子间相互作用以加速改变生命疗法的AI公司，今天宣布了其7000万美元的A轮融资。

The fundraise was led by Menlo Ventures, including investment from their Anthology Fund, a joint partnership with Anthropic to identify and back promising AI companies, with participation from new investors Yosemite, DST Global Partners, SV Angel, Avenir, DCVC, and others. It also included existing investors Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, and Fred Ehrsam, among others..

本轮融资由 Menlo Ventures 领投，其中包括来自他们与 Anthropic 联合成立的基金 Anthology Fund 的投资，该基金旨在识别并支持具有潜力的人工智能公司，同时新投资者包括 Yosemite、DST Global Partners、SV Angel、Avenir、DCVC 等。此外，现有投资者 Thrive Capital、OpenAI、Dimension、Neo、Lachy Groom 和 Fred Ehrsam 等也参与其中。

“Progress towards game-changing drugs and treatments is far too slow, stymied by costly trial-and-error experiments,” said Joshua Meier, CEO and co-founder. “Chai Discovery exists to push the boundaries of what's possible in this field, applying frontier AI to transform biology from science to engineering, so that breakthroughs can be designed rather than simply discovered.”.

“向具有变革性药物和治疗的进展过于缓慢，受到昂贵的试错实验的阻碍，”首席执行官兼联合创始人约书亚·梅尔说。“Chai Discovery 的存在是为了突破这一领域的可能性边界，应用前沿人工智能将生物学从科学转变为工程，从而设计出突破性成果，而不仅仅是发现。”

Chai was founded in 2024 by Joshua Meier (ex AI drug discovery firm Absci; Facebook AI; OpenAI), Jack Dent (ex Eng and Product leader at Stripe), and AI researchers Matthew McPartlon and Jacques Boitreaud.

Chai 由 Joshua Meier（前 AI 药物发现公司 Absci、Facebook AI、OpenAI）、Jack Dent（前 Stripe 工程与产品负责人）以及 AI 研究人员 Matthew McPartlon 和 Jacques Boitreaud 于 2024 年创立。

Mikael Dolsten M.D., PhD., the former Pfizer Chief Scientific Officer responsible for advancing 150 molecules into clinical trials and delivering 36 approved medicines, is joining the company’s board of directors.

迈克尔·多尔斯特（Mikael Dolsten）医学博士、哲学博士，前辉瑞首席科学官，曾推动150种分子进入临床试验并成功交付36种获批药物，现将加入公司董事会。

“I’m proud to join Chai Discovery and redefine biology from science into engineering,” Dr. Dolsten said. “This is going to be an incredible journey with an incredible team.”

“我很自豪能加入Chai Discovery，将生物学从科学重新定义为工程学，”Dolsten博士说。“这将是一段与卓越团队共同开启的非凡旅程。”

Last year, the company closed a $30 million seed round led by Thrive Capital, OpenAI, and Dimension. Soon after, they released Chai-1, an open-source foundation model for molecular structure prediction that performs at the state-of-the-art

去年，该公司完成了由Thrive Capital、OpenAI和Dimension领投的3000万美元种子轮融资。不久之后，他们发布了Chai-1，这是一个用于分子结构预测的开源基础模型，性能达到了最先进的水平。

Last month, the team unveiled a further leap in AI-driven drug discovery with their Chai‑2 breakthrough, delivering fully de novo antibody design with a near-20% hit rate. By contrast, traditional lab based methods often have to screen millions to billions of antibodies to find hits, and the previous state of the art for computational methods was only 0.1%..

上个月，该团队通过其Chai-2突破在人工智能驱动的药物发现领域实现了又一次飞跃，实现了近20%命中率的完全从头抗体设计。相比之下，传统的实验室方法通常需要筛选数百万到数十亿个抗体才能找到命中，而之前最先进的计算方法命中率仅为0.1%。

When inputting only the target antigen and epitope, Chai‑2 can generate successful binders from scratch against a wide variety of targets. This means that scientists working on a target antigen, a specific disease-causing protein such as a virus or type of cancer, can use Chai-2 to design, from scratch, completely new antibodies that can hit the right spot..

仅输入目标抗原和表位时，Chai-2 能够从头开始生成针对各种目标的成功结合物。这意味着研究某种目标抗原（如导致特定疾病的蛋白质，像病毒或某种癌症）的科学家可以使用 Chai-2 从零设计出全新的抗体，精准命中目标位置。

“Before Chai-2, the process was not unlike searching a giant bunch of keys for the right fit for a lock—but there are millions of keys,” said Matthew McPartlon, co-founder. “Now, it’s like having a master locksmith design exactly the right shape key, based only on your description of the lock. A company had spent more than three years and over $5m on a problem.

“在Chai-2之前，这个过程很像在一大串钥匙中寻找适合锁的那把——但那里有数百万把钥匙，”联合创始人马修·麦克帕特伦说道。“现在，这就像是让一位资深锁匠仅根据你对锁的描述就设计出完全匹配的钥匙形状。一家公司曾花费超过三年时间和500多万美元来解决一个问题。”

With Chai-2, we were able to find an experimentally validated solution within two weeks.“.

通过Chai-2，我们能够在两周内找到一个经过实验验证的解决方案。

The funding will be used to further develop the Chai platform, applying it toward previously inaccessible targets, and onboarding select partners.

这笔资金将用于进一步开发Chai平台，将其应用于之前无法触及的目标，并引入选定的合作伙伴。

“Chai is an exceptional technical team building foundation models for biology to transform drug discovery,“ said Greg Yap, Partner at Menlo Ventures. “Chai-2 demonstrates amazing progress in antibody design, and we have seen a meaningful fraction of the biotech industry already apply for Chai-2 access.

“Chai 是一家卓越的技术团队，致力于为生物学构建基础模型以变革药物发现，”Menlo Ventures 的合伙人 Greg Yap 表示。“Chai-2 在抗体设计方面展现了惊人的进展，我们已经看到相当一部分生物技术行业申请了 Chai-2 的使用权限。

At Menlo, we invest deeply in both AI foundation models and technology-enabled biology–we believe Chai can help create better medicines faster.”.

在门洛，我们深入投资于人工智能基础模型和技术赋能的生物学——我们相信Chai可以帮助更快地创造更好的药物。

For more information on Chai Discovery and its platform, visit https://www.chaidiscovery.com.

有关Chai Discovery及其平台的更多信息，请访问https://www.chaidiscovery.com。

About Chai Discovery

关于Chai Discovery

Chai Discovery builds frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules, the fundamental building blocks of life. Its mission is to transform biology from science into engineering. The team hails from pioneering research and applied AI companies such as OpenAI, Meta FAIR, Stripe, and Google X, and is backed by top investors including OpenAI, Thrive Capital, Menlo Ventures and Dimension..

Chai Discovery 构建前沿人工智能，用于预测和重新编程生化分子之间的相互作用，这些分子是生命的基本组成部分。其使命是将生物学从科学转变为工程学。团队成员来自开创性研究和应用人工智能公司，如 OpenAI、Meta FAIR、Stripe 和 Google X，并受到包括 OpenAI、Thrive Capital、Menlo Ventures 和 Dimension 在内的顶级投资者支持。

Contact:

联系人：

press@chaidiscovery.com

press@chaidiscovery.com